(Total Views: 430)
Posted On: 12/19/2020 4:15:12 PM
Post# of 22465
Innova's PR indicates to me that the QMCH is only one aspect or manifestation of testing within what QMC can do in pharma. It's the point of interaction with the public. Innova is doubling it manufacturing for that business from 4M to 8M tests/day.
The Biolab acquisition adds fast-turnaround for PCR at many locations. Evidently there is a need for PCR to confirm antigen tests under some conditions and this brings that capability in-house, giving Innova a full testing package to offer and control over the PCR testing so it can be uniformity entered into the QMCH reporting system.
Lastly it brings R&D in-house and in the USA which may affect approvals, response time, development, etc., as well as developing tests.
The Biolab acquisition adds fast-turnaround for PCR at many locations. Evidently there is a need for PCR to confirm antigen tests under some conditions and this brings that capability in-house, giving Innova a full testing package to offer and control over the PCR testing so it can be uniformity entered into the QMCH reporting system.
Lastly it brings R&D in-house and in the USA which may affect approvals, response time, development, etc., as well as developing tests.
(1)
(0)
